Edwards Lifesciences CORP Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NYSE
Vanguard Capital Management has filed a Schedule 13G reporting a 7.54% beneficial ownership stake in Edwards Lifesciences Corp.
NYSE
The Vanguard Group filed an amendment to its Schedule 13G for Edwards Lifesciences Corp, reporting zero beneficial ownership following an internal realignment.
NYSE
SCHEDULE 13G/A: BlackRock Boosts Edwards Lifesciences Stake to 7.5%
BlackRock, Inc. has filed an amended Schedule 13G, reporting a beneficial ownership of 7.5% of Edwards Lifesciences Corp's common stock.
NYSE
Wellington Management Group LLP and its affiliates reported a 3.38% beneficial ownership stake in Edwards Lifesciences Corporation as of June 30, 2025.
NYSE
The Vanguard Group has filed an amended Schedule 13G, reporting an 11.72% beneficial ownership stake in Edwards Lifesciences Corp as of December 31, 2024.